Resverlogix Corp.  

(Public, TSE:RVX)   Watch this stock  
Find more results for RVX
0.00 (0.00%)
Jul 31 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.77 - 1.83
52 week 0.41 - 3.13
Open 1.81
Vol / Avg. 5,266.00/44,420.00
Mkt cap 192.06M
P/E     -
Div/yield     -
EPS -0.28
Shares 105.07M
Beta 1.77
Inst. own     -

Key stats and ratios

Q2 (Apr '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -377.26% -151.54%
Return on average equity - -
Employees 19 -
CDP Score - -


300-4820 Richard Rd SW
+1-403-2549252 (Phone)
+1-403-2568495 (Fax)

Website links


Resverlogix Corp. is a Canada-based clinical stage biotechnology company. The Company is engaged in developing compounds involving ApoA-I production. The Company’s RVX-208 is a molecule, developed for the treatment of clinical conditions, including atherosclerosis, Diabetes Mellitus and Alzheimer’s disease. RVX-208 is the first bromodomain and extra terminal domain (BET) inhibitor in clinical trials. New compounds arising from Company's epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases, including neurodegenerative diseases and diabetes mellitus. The Company’s clinical cardiovascular programs include cardiovascular disease and atherosclerosis, Apoa-I, HDL and reverse cholesterol transport, and RVX-208 and MOA.

Officers and directors

Peter Johann Ph.D. Independent Chairman of the Board
Donald J. McCaffrey President, Chief Executive Officer, Secretary, Director
A. Brad Cann CA Chief Financial Officer
Jan O. Johansson M.D., Ph.D. Senior Vice President - Medical Affairs
Kenneth Lebioda Senior Vice President - Business & Corporate Development
Michael T. Sweeney M.D. Senior Vice President - Clinical Development
Norman Wong M.D. Chief Scientific Officer
Kelly B. McNeill Independent Director
Eldon R. Smith M.D. Independent Director
Age: 75
Kenneth J. Zuerblis Independent Director
Age: 56